A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
367actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-29 | actual | When the study began enrolling |
| Primary completion | 2025-05-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-27 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Pain
Interventions
- Drug: VX-993
- Drug: HB/APAP
- Drug: Placebo (matched to VX-993)
- Drug: Placebo (matched to HB/APAP)
Primary outcome
what the primary-completion date above is the date OFTime-weighted Sum of Pain Intensity Difference (SPID) as Recorded on the Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48)
measured From 0 to 48 Hours After the First Dose of Study Drug
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed